NattoPharma (NATTO)

[holmes]

Her er det 3 som gjerne vil bytte plass med hverandre

[TekBot]

13/02-2019 07:57:16: (NATTO.OAX) NATTOPHARMA ENHANCES OFFERING WITH TECHNOLOGY PARTNERSHIP

The world leader in Vitamin K2 expands its product portfolio, developing a new
ingredient with a technologically advanced delivery system for fast-growing,
dynamic supplement categories
…

Vis børsmeldingen

Oslo, Norway (13 FEB 2019) - NattoPharma has reached an accord with Inventia
Healthcare Ltd. and Laila Nutraceuticals that provides NattoPharma with the
exclusive rights in core markets to add Inventia and Laila’s proprietary
ingredient, in the mood and energy segments, supported by unique composition of
actives and proprietary novel technology, to its clinically validated portfolio.

Not only does the agreement bring an exciting innovation to a dynamic ingredient
category, but it is also the first ingredient NattoPharma will introduce
separate from the Vitamin K2 as menaquinones segment.

“NattoPharma has been incubating a number of new concepts based on our high
standard of clinical validation confirming true health benefits,” says
NattoPharma CEO Kjetil Ramsøy. “Laila’s long, rich history in developing
superior actives and Inventia’s entry into Nutraceuticals with its
pharmaceutical background equates to tighter product specifications, stringent
quality standards, and an insistence upon delivering products based on science,
which is perfectly in line with NattoPharma’s principles.”

“We are delighted to partner with Inventia and NattoPharma to bring
Nutraceutical Ingredients to the market that address consumer needs and are
backed by robust science and quality,” says Kiran Bhupathiraju, CEO Laila
Nutraceuticals.

“We are excited to sign this agreement with NattoPharma, as it combines the
market reach of NattoPharma, superior active from Laila, along with the
technology advantage of Inventia Healthcare to provide customers with more
benefits,” says Vishal Shah, Whole Time Director at Inventia. “Our three
companies are likeminded in holding ourselves to the highest standards, ensuring
the ingredients we put in the marketplace are supported by substantial evidence
confirming efficacy and safety. This partnership further validates the
application of our diverse delivery platforms and its applications in the
Nutritional space for the betterment of human health.”

Inventia Healthcare Ltd. is a 33-year-old innovative drug delivery company that
specializes in novel, science-based, oral delivery technologies for
Pharmaceutical applications. With a state-of-the-art research and development
center approved by the Ministry of Science and Technology, Government of India,
Inventia is well equipped to undertake formulation and development projects on
Novel Drug Delivery Systems in the Nutraceuticals segment.

Laila Nutraceuticals is a world leader in developing innovative botanical
ingredients that have become top sellers across various countries over the last
several decades. With a rich heritage of 44 years, Laila Nutraceuticals has
state of the art GLP laboratories with 150 scientists dedicated to research and
innovation of botanical actives coupled with cGMP compliant, NSF GMP certified
manufacturing facilities that have been approved by US FDA and other regulatory
agencies.

Ramsøy adds, “Inventia’s delivery technology and Laila’s superior ingredient
composition is a perfect complement to our existing ingredient family in that it
has a long history of safe use, along with the requisite clinical evidence that
our customers demand and expect. We continue in the substantiation process,
including human clinical studies validating superior health benefits, which
signify real process for our project. Given the sales cycle and timing, we would
expect to begin realizing commercial sales in Q1 2020.”

XXX

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the supplement industry world leader in
vitamin K2 research and development. NattoPharma is the exclusive international
supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as
menaquinone-7 (MK-7) with guaranteed actives and stability, clinical
substantiation, and international patents granted and pending; and now the new
MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has
a multi-year research and development program to substantiate and discover the
health benefits of Vitamin K2 for applications in the marketplace for functional
food and dietary supplements, in addition to exclusive access to the research
efforts of its pharmaceutical arm, Kaydence Pharma AS (est. 2017), outside of
the pharmaceutical domain. With a global presence, the company established its
North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma
R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or
www.menaq7.com.

For more information, please contact:

Kate Quackenbush, NattoPharma Director of Communications

Phone: 609-643-0749 x 220; E-mail: kate.quackenbush@nattopharma.c

http://www.netfonds.no/quotes/release.php?id=20190213.OBI.20190213S34

[TekBot]

13/02-2019 08:00:23: (NATTO.OAX) NATTO: STRONG GROWTH AND POSITIVE RESULT

Oslo, Norway (13 February 2019) - NattoPharma increased revenues by 52% in the
second half of the year and delivered a positive net result in the half year and
for the full year 2018. This is coupled with a strong financial position with no
…

Vis børsmeldingen

interest-bearing debt and an equity ratio of 74,5% as at December 31st, 2018.

"We are very pleased to deliver a strong second half fueled by a record fourth
quarter with Product Revenues of approximately NOK 31 million and an EBITDA of
10%. This is the first full year where the Group has a positive net result,
demonstrating our ambition of profitable growth. We are especially pleased that
we have achieved this already in the first year following the spin-off of the
pharma business into Kaydence Pharma AS.

We are also increasing our focus on growing shareholder value. In December we
signed an agreement for 2019 with Nordea Markets for Commissioned Research and
anticipate the first report to be available in early March. At the same time, we
are returning to a quarterly reporting cycle." Kjetil Ramsøy, CEO NattoPharma.

Financial highlights:

±---------------±-----±------±-----------±-----±-----±-----------+
/(mnok) /H2’18 / H2’17 / Change / 2018 / 2017 / Change /
±---------------±-----±------±-----------±-----±-----±-----------+
/Product Revenue / 54,5 / 36,0 /18,6 (+52%) /101,7 / 66,4 /35,3 (+53%) /
±---------------±-----±------±-----------±-----±-----±-----------+
/Gross Margin /44,3% /48,8 % / -4,5%/ 43,1%/47,4% / -4,3% /
±---------------±-----±------±-----------±-----±-----±-----------+
/Adj. EBITDA / 4,2 / 3,8 / 0,3 / 6,7 / 5,3 / 1,4 /
±---------------±-----±------±-----------±-----±-----±-----------+
/Net profit / 3,2 / -0,9 / 4,1 / 1,8 / -4,1 / 5,8 /
±---------------±-----±------±-----------±-----±-----±-----------+

Please find attached the Nattopharma Group 2018 Second Half and Preliminary Full
Year Earnings Release.

A presentation will be held via webcast at 10 am CET, Wednesday 13thFebruary
2019, followed by a Q&A session.

Please follow the below link to join the webcast;

http://webtv.hegnar.no/presentation.php?webcastId=97603094

For more information, please contact:

Kjetil Ramsøy

CEO, NattoPharma

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the N

http://www.netfonds.no/quotes/release.php?id=20190213.OBI.20190213S44

[holmes]

Dette ser veldig bra ut ved første øyekast.

[TekBot]

13/02-2019 08:36:16: (NATTO.OAX) NATTO: OPTIONS GRANTED

Oslo, Norway (13 February 2019) - Based on the power of attorney granted at the
annual general meeting of NattoPharma ASA (“NattoPharma” or “Company”) on May
30th, 2018, and the option program related to defined operational objectives
…

Vis børsmeldingen

approved by the Board of Directors in 2018, the Board of Directors of
NattoPharma has in board proceedings February 12th, 2019 granted a total of 292
500 options to executive management, other employees and strategic partners.
Options are granted based on performance against defined criteria and metrics.

The following persons on the executive management team have been granted
options;

Name Granted Options Options Prior to Grant Options after Grant
Kjetil 100 000 125 100 225 100
Ramsøy, CEO
& CFO

Other employees and partners have been granted a total of 192 500 options.

The options have an exercise price equal the closing price on Oslo Axess on
February 12th, 2019, which is equal to NOK 9,00.

The options granted are vested immediately and may be exercised up to and
including March 31st, 2023.

X X X

For more information, please contact:

Kjetil Ramsøy,

CEO, NattoPharma

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

http://www.netfonds.no/quotes/release.php?id=20190213.OBI.20190213S50

[holmes]

Skal prøve å summere opp hovedpunktene

• Nordea skal gjøre oppdragsanalyse for Natto, kommer trolig første oppdatering i mars.
• Ny ingrediens skal lanseres trolig mot slutten av året, med inntekter forventet fra Q1 2020.
• Omsetningen runder 100mnok fra varesalg
• Bruttomargin stiger fra h1 til h2 41.67% til 44.30% forhåpentligvis kan vi se enda høyere bruttomargin i 2019.
• EBIT (og cashflow og nettoresultat) i pluss for første gang på hvor mange år

Dette kaller jeg stabil vekst (disclaimer: har lagt inn 35% vekst for inneværende år, prøvd å være litt konservativ, men vi har ikke fått noen guiding her enda, blir spennende å se hva Nordea legger seg på)

Balansen
Current assets 64 mnok
Current liabilities 22mnok
Net 42mnok

I tillegg har Kaydence et lån på 46 mnok.

I tillegg sitter NattoPharma på 46.41% av aksjene i Kaydence med en antatt verdi på ca 34 mnok.

Dette regnestykket blir jo veldig snodig når mcap på NP er rundt 180 mnok. Trekker man fra disse postene blir det igjen 58 mnok for et selskap som vokser kraftig organisk, selger allerede for over 100 millioner og går i pluss!

[Christian]

Heh, aksjen opp 20% på 177.000 kr i omsetning

Sitter på en ikke altfor stor beholdning, har ikke økt på 8-9 tallet og kommer nok til å angre på det, men greit nok. Når er det guiding for 2019 er forventet?

[holmes]

I mars så kommer vi trolig til å få den første analysen fra Nordea, så tenker det blir den beste “guidingen” vi får fremover.

Kan jo være det blir sagt noe her også

The same day, starting at 10:00 am, the company will host a webcast with a presentation of the results, followed by an online Q&A session.
Please follow the below link to join the web-cast, http://webtv.hegnar.no/presentation.php?webcastId=97603094

[Logon]

Sitter i ro med min post
Endelig løsner det litt

[TekBot]

13/02-2019 16:30:02: (NATTO.OAX) NATTO: MANDATORY NOTIFICATION OF TRADE

On 13th February 2019, Pro AS bought 10,000 shares in NattoPharma ASA at an
average price of NOK 10,19 per share. After this transaction Pro AS control
1,966,310 shares in NattoPharma ASA. Pro AS is wholly owned by Sjur Thorsheim,
…

Vis børsmeldingen

member of the Board of Directors in NattoPharma ASA.

http://www.netfonds.no/quotes/release.php?id=20190213.OBI.20190213S129

[holmes]

Golden cross nærmer seg. Får satse på at det kommer mer volum her fremover. I går ble det i hvert fall omsatt for en halv million, ikke allverdens, men ok for Natto. Så langt i dag omsatt for TUSEN KRONER

[TekBot]

14/02-2019 16:29:49: (NATTO.OAX) MANDATORY NOTIFICATION OF TRADE

On 14th February 2019, Stefan Halldén bought 3,000 shares in NattoPharma ASA at
an average price of NOK 9,80 per share. Stefan Halldén is a member of the Board
of Directors in NattoPharma ASA, and Chairman of the Board and major owner in
…

Vis børsmeldingen

Life Science Sweden AB, a large shareholder in NattoPharma ASA.

After this transaction Stefan Halldén control 84,800 shares in NattoPharma ASA.
Life Science Sweden AB control 2,182,362 shares in NattoPharma ASA.

http://www.netfonds.no/quotes/release.php?id=20190214.OBI.20190214S165

[holmes]

Golden cross bekreftet. Neste “trigger” er vel Nordea analysen som kommer senere i februar eller tidlig mars.

[holmes]

Omsetning per aksje vs kursutvikling

[Christian]

Digger illustrasjonen, ledelsen fortsetter å laste opp til lave kurser uten reaksjon heller.

[Alex]

Volumet er elendig her, men i tillegg synes jeg dette handelsmønstret ser mistenkelig ut.

7500 aksjer ligger åpent på salg på 10.5

Følger litt mer på NATTO enn tidligere, men det blir nok kun en lyttepost her for min del.

[holmes]

Ja det er fortsatt svært lav interesse for aksjen. Spørsmålet folk har begynt å stille seg tror jeg er om Nordea analyse, kvartalsrapporter og forhåpentligvis økende overskudd for hver rapport kan bedre på dette. Derfor har selgere begynt å krype oppover, tidligere lå de på 8.50, nå ligger de på 10.50, en bedring det da.

[Christian]

De forrige gangene så har aksje falt tilbake etter gode nyheter, folk forventer det denne gangen også. Derfor er det ingen som “tror” på oppgangen denne gangen heller. Har sittet i denne aksjen for lenge, kjøpte den når jeg hadde en annen kjæreste

[holmes]

7500 aksjer ligger åpent på salg på 10.5

Not any more

[Christian]

Det ble den posten spist ja. Tror jaggu det kan være duket for oppgang her.